How PBM-Owned Specialty Pharmacies Impact Wholesale Drug Distributors in 2026

CVS Caremark, Express Scripts, and OptumRx now control 79% of the U.S. prescription drug market and operate their own specialty pharmacy networks, cold chain logistics, and wholesale distribution arms. This vertical integration has fundamentally altered the competitive landscape for independent wholesale drug distributors, particularly those serving specialty pharmacies outside these integrated systems.

Regulatory Framework for PBM Vertical Integration

The Federal Trade Commission's June 2024 report on pharmacy benefit managers identified vertical integration as a primary structural concern in pharmaceutical distribution. Under current law, PBMs face no federal restrictions on owning pharmacies, distributors, or manufacturers — creating what the FTC characterized as "inherent conflicts of interest in steering prescriptions and setting reimbursement rates."

State responses have been fragmented. As of January 2026, 18 states have enacted "any willing provider" laws requiring PBMs to contract with independent specialty pharmacies. Seven states (Arkansas, Louisiana, Mississippi, North Dakota, Oklahoma, South Dakota, West Virginia) have banned spread pricing and mandatory mail-order provisions that favor PBM-owned pharmacies. However, ERISA preemption limits state authority over employer-sponsored plans, which represent 56% of the commercial insurance market.

The Drug Supply Chain Security Act (21 USC 360eee) applies equally to PBM-owned and independent distributors. All wholesale drug distributors must maintain licensure in each state where they operate, comply with transaction history and statement requirements under DSCSA, and register with the FDA under 21 CFR Part 207. Vertical integration does not exempt entities from these baseline requirements.

The Mechanics of PBM-Owned Distribution Networks

Express Scripts operates Accredo Health Group (specialty pharmacy) and HealthTrans (wholesale distribution). CVS Health operates CVS Specialty (pharmacy), Coram (infusion services), and Omnicare (institutional pharmacy). OptumRx operates OptumRx Specialty Pharmacy and relies on parent company UnitedHealth Group's Optum Infusion for specialty cold chain logistics.

These integrated networks handle product selection, procurement, distribution, dispensing, and reimbursement determination within a single corporate structure. When a prescription requiring specialty distribution is adjudicated through Express Scripts' PBM, the claim may be steered to Accredo (pharmacy), fulfilled by HealthTrans (distribution), and reimbursed based on rates set by Express Scripts (PBM) — all within the same entity.

Independent wholesale distributors compete for the 21% of specialty pharmacy volume not controlled by the Big Three PBMs. This includes prescriptions filled by independent specialty pharmacies, health system-owned specialty pharmacies, and regional PBM networks.

Operational Impact on Independent Distributors

Formulary access restrictions: PBM-owned pharmacies receive preferential formulary placement. In the oncology category, CVS Specialty fills 34% of biosimilar prescriptions despite representing 22% of specialty pharmacy market share (IQVIA 2025 data). Independent distributors serving independent pharmacies face reduced volume as prescriptions are steered toward PBM-owned channels.

Pricing pressure: PBM-owned distributors can cross-subsidize distribution costs using PBM rebate revenue or pharmacy dispensing margins. Independent distributors operate on distribution margin alone, typically 3-5% for specialty products. When competing for health system contracts, PBM-owned distributors can underbid by subsidizing losses in distribution with profits in pharmacy or rebate administration.

Cold chain capability requirements: Specialty pharmaceuticals represent 50% of U.S. drug spending but only 2% of prescriptions (IQVIA 2025). Many specialty products require 2-8°C cold chain throughout distribution. PBM-owned networks have built dedicated temperature-controlled distribution centers in 18 markets. Independent distributors must either build comparable infrastructure or partner with 3PL cold chain providers — both capital-intensive options.

DSCSA compliance burden: While DSCSA requirements apply equally, integrated networks achieve compliance efficiencies by controlling multiple nodes. CVS Health can exchange VRS transaction data between its own distribution and pharmacy entities without external ATP verification. Independent distributors must implement full ATP processes for each transaction with downstream trading partners.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PL cold chain providers, of which 847 entities (66%) list specialty pharmaceutical distribution or temperature-controlled logistics as a service line. The average compliance score across all entities is 51/100, placing the majority in the "Fair" tier — indicating active state licensure and FDA registration, but limited NABP accreditation penetration.

Among the 847 specialty-focused entities, compliance score distribution skews slightly higher: 24 entities (3%) score in the Excellent range (76-100 points), 198 (23%) in Good (51-75 points), 597 (71%) in Fair (26-50 points), and 28 (3%) in Poor/Minimal (<25 points). This distribution reflects a fundamental challenge: only 63 entities in the entire directory hold NABP accreditation (formerly VAWD), which represents 25 points of the 100-point compliance score. The vast majority of distributors operate with state licenses and FDA registration but lack third-party verification of their wholesale operations.

When competing against PBM-owned distributors — all of which hold NABP accreditation and multi-state licensure — independent distributors with Fair-tier scores face a compliance perception gap during vendor qualification processes. A health system procurement team evaluating two distributors may default to the PBM-owned entity if the independent alternative lacks accreditation or has incomplete multi-state coverage.

For QA managers and compliance officers evaluating specialty distributors:

• Cross-reference PBM ownership — ColdChainCheck entity profiles include parent company data where publicly disclosed. OptumRx Specialty Pharmacy, CVS Specialty, and Accredo Health Group are tagged with UnitedHealth Group, CVS Health, and Cigna ownership respectively. If sourcing specialty products, verify whether your distributor operates independently or within an integrated PBM network.

• Verify NABP accreditation for specialty volume — Of the 63 NABP-accredited entities in ColdChainCheck, 41 specifically list specialty or cold chain services. Use the directory filters to identify accredited specialty distributors in your region as benchmarks during vendor qualification.

• Monitor state licensure breadth — PBM-owned distributors typically hold licenses in 45+ states. Independent distributors average 12 state licenses. If your organization operates multi-state specialty programs, confirm distributor licensure in each dispensing state using ColdChainCheck's state license coverage data.

• Track enforcement actions — ColdChainCheck flags 73 entities with FDA recalls, warning letters, or state enforcement actions on record. When evaluating independent distributors competing with PBM-owned alternatives, check compliance history at the entity level. A clean record strengthens the case for using an independent channel despite pricing pressure.

For related regulatory coverage on specialty pharmaceutical distribution and DSCSA compliance, see ColdChainCheck's compliance guides.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Verify all compliance requirements with the relevant state board of pharmacy, FDA, or legal counsel before making procurement or vendor qualification decisions.